Market Overview

PTC Therapeutic, Roche Announce Joint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development

Related PTCT
16 Stocks Moving In Friday's Pre-Market Session
Technical Alert: PTC Therapeutics Continues Lower
PTC Therapeutics poised for $20M milestone from licensee Roche on advancement of mid-stage study of RG7916 in spinal muscular atrophy; shares ahead 4% premarket (Seeking Alpha)

PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (OTC: RHHBY), announced today that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers. SMA is a genetic neuromuscular disorder that leads to muscle weakness and mobility impairment and is considered the leading genetic cause of death in infants and toddlers.   

See full press release

Posted-In: News Guidance Buybacks Global


Related Articles (RHHBY + PTCT)

View Comments and Join the Discussion!